The group's principle activity is to develop new medicines with exceptional safety and efficiency for neurological diseases. The group's product includes KNS-760604 for the treatment of amyotrophic lateral sclerosis (ALS). The group operates from United States.
Executive Information
Name
Title
Email
Michael Bozik
CEO, Pres.
N/A
Evan Ingersoll
COO, Sr. VP - Clinical Research, Business Operations